Effect of Antiretrovirals on Renal Function of HIV/AIDS Patients at Two Hospitals in Yaounde, Cameroon

Mann Elate Lea Mbassi Yves1,2*, Wambe Gilles Verland1 and Paana Alima Marguerite Cebrael2

1Faculty of Health Sciences, Yaoundé Protestant University Institute, Protestant University of Central Africa, Yaoundé, Cameroon
2Faculty of Science, Laboratory for Public Health Biotechnology, University of Yaoundé I, Yaoundé, Cameroon

*Corresponding author: Mann Elate Lea Mbassi Yves, Faculty of Health Sciences, Yaoundé Protestant University Institute, P.O. Box 4011, Protestant University of Central Africa and Faculty of Science; Laboratory for Public Health Biotechnology, P.O. Box 8094, University of Yaoundé I, Yaoundé, Cameroon, Tel: +237-696-024-857

Abstract

Background: Antiretroviral therapies (ART) have been reported to have renal toxicity. However, there is a lack of data on the toxicity of ART in sub-Saharan countries, especially in Cameroon. More studies on their contribution to renal dysfunction in natives from this region are required.

Methods: HIV/AIDS patients undergoing eleven different first-line ART at two hospitals in Yaoundé, Cameroon, were selected in this study. Retrospective and prospective data of serum urea and creatinine were collected, and the estimated Glomerular Filtration Rate (eGFR) was calculated. Wilcoxon signed-rank test, paired t-test and chi-square test were used for statistical analysis. The level of significance was set at p < 0.05.

Results: Out of 187 participants, there were 134 women (71.66%). The age ranged from 24 to 77 years, with a mean age of 42.47 ± 10.68. The mean serum urea level increased after ART initiation for D4T40 + 3TC + NVP (p = 0.011) and TNF + 3TC + EFV + INH (p = 0.03) regimen in women and for TNF + 3TC + EFV + CTM (p = 0.03) in men. It decreased for D4T40 + 3TC + NVP (p = 0.03) in men. The mean serum creatinine increased for women following regimen AZT + TNF + NVP (p = 0.022) and D4T40 + 3TC + NVP (p = 0.028), and for men on AZT + TNF + NVP (p = 0.03). There was rather a decrease in blood creatinine for women on AZT + 3TC + NVP regimen (p = 0.0032). Mean eGFR decreased for patients on AZT + TNF + NVP (p = 0.015), D4T40 + 3TC + NVP (p = 0.016) and TNF + 3TC + EFV + INH (p = 0.03) regimen. The eGFR dropped below the threshold of 60 ml/min/1.73 m² for 5/12 patients on D4T40 + 3TC + NVP, 2/6 patients on TNF + 3TC + EFV + INH, 1/4 patients on TNF + 3TC, 6/74 patients on TNF + 3TC + EFV and 1/28 patients on TNF + 3TC + EFV + CTM regimen. However, a significant increase of the eGFR has been observed for treatments with AZT + 3TC + NVP (p = 0.001), 3TC + TNF + EMB (p = 0.032) and D4T30 + 3TC + EFV (p = 0.032) regimen.

Conclusion: Antiviral therapy with stavudine 40 mg (D4T40) or tenofovir-based regimen could lead to renal toxicity. However, the results show that D4T30 + 3TC + EFV, 3TC + TNF or AZT + 3TC + NVP combinations would be rather protective for renal function, and should be recommended.

Keywords
HIV/AIDS, Antiretroviral therapy, Renal toxicity

Abbreviations

3TC: Lamivudine; ABC: Abacavir; ART: Antiretroviral Therapy; AZT: Zidovudine; CTM: Cotrimoxazole; D4T30: Stavudine 30 mg; D4T40: Stavudine 40 mg; EFV: Efavirenz; eGFR: Estimated Glomerular Filtration Rate; EMB: Emtricitabine; HAART: Highly Active Antiretroviral Therapy; INH: Isoniazid; NVP: Nevirapine; TNF: Tenofovir

Introduction

HIV/AIDS is one of the leading causes of death in the world. According to an UNAIDS report [1], in 2019, 38 million people were living with HIV/AIDS and 1.7 million people were newly infected. HIV/AIDS causes a decrease in immune defenses leading to immunosuppression, making the patient vulnerable to complications including organ damage and/or metabolic disorder [2]. Thus, 32.7 million people have died from AIDS-related
illnesses since the start of the epidemic. However, since the advent of triple antiretroviral therapy in 1996, mortality due to this infection has decreased by more than 75% [1]. The use of antiretrovirals (ARV) has therefore become widespread throughout the world, so that 25.4 million people were accessing antiretroviral therapy in 2019 [1].

Paradoxically, the use of certain antiretroviral treatments that are particularly effective against HIV/AIDS has been accompanied by toxic side effects on vital organs such as the pancreas, kidneys, liver, giving the emergence of morphological changes in patients treated with these drugs. Peculiarly, because the kidneys play a major role in the metabolism and excretion of most drugs including ARVs, they are routinely exposed to high concentrations of these drugs, their metabolites, or both [3], which can damage them. In the proximal tubule, there is a high rate of blood flow and consequently a high level of toxins to be processed, so this portion of the nephron is at particular risk of developing damage due to drug toxicity [4]. Thus, HIV treatment by ARVs may increase the risk of kidney damage due to drug-drug interaction or the nephrotoxicity of the drugs themselves [5-11]. A kidney transplant is not an easy option since it is very expensive. Although the option of hemodialysis is still possible, it is also time consuming and expensive. It is therefore necessary to carry out comparative studies of the effects of the different drug combinations, in order to identify those with undesirable side effects, and to make dose adjustments.

However, the pharmacogenetic research has uncovered significant differences between racial and ethnic groups in the metabolism, clinical effectiveness, and side effect profiles of many clinically important drugs. These differences must be taken into account in the design of therapeu tic substitution and step-care protocols [12,13]. Sixty-nine percent (more than 2/3) of the total HIV-positive people are in sub-Saharan Africa [1]. In Cameroon, a sub-Saharan country with an exclusively black population, 23,000 new HIV infected cases were diagnosed in 2018 and 540,000 people were living with HIV. The prevalence of HIV amongst the population age 15 to 49 years in Cameroon in 2018 was estimated to be 3.6%. Furthermore, 52% of people living with HIV in the country were on ARV treatment the same year [14]. In Cameroon, ARVs nephrotoxicity has been very poorly studied [15-18]. But based on research done elsewhere in the world, stavudine has been progressively eliminated from ART protocols of patient follow-up in Cameroon, due to possible side-effects [19,20], and replaced by the tenofovir disoproxil fumarate (TDF). TDF is a reverse transcriptase nucleotide inhibitor used in first and second line of ART. The efficiency and tolerability of TDF has been evaluated by some studies worldwide [8,10,21,22]. This drug is known for its possible side-effects such as renal dysfunctions (tubulopathies, nephrotoxicity, acute or chronic kidney impairment). Assessing renal toxicity due to TDF or other ARV will allow better monitoring of patients on these molecules in Cameroon. Studies in this direction could help to determine the least toxic combinations applicable to Cameroonian or even African populations in general, and would undoubtedly be a scientific contribution that could interest global researchers.

For the evaluation of potential renal toxicity, the monitoring of serum creatinine and serum urea has been introduced among the fundamental biological exams during HIV patient follow-up. Renal impairment is often classified based on the GFR determined by the creatinine clearance method. Accordingly, there are normal values (≥ 90 ml/min/1.73 m²), mild (60-89 ml/min/1.73 m²), moderate (30-59 ml/min/1.73 m²), severe (15-29 ml/min/1.73 m²) and renal failure (< 15 ml/min/1.73 m²) [23]. Renal dysfunction was defined as Crcl < 60 ml/min/1.73 m².

The aim of the present study is to evaluate, by measuring the serum urea and creatinine concentrations, and by the estimation of the glomerular filtration rate, the impact of 11 combinations of first-line ART on renal function of HIV/AIDS patients followed in Cameroon.

Material and Methods

Type and study location

A study was conducted between 2017 and 2020, with retrospective and prospective data collection in a two-phase design. In the first phase, the patients’ medical records were reviewed. A second phase was conducted prospectively, during a study period of one month: May-June 2017 at the Accredited Treatment Center (ATC) of AIDS of Essos Hospital; July-August 2020 at the ATC of the Jamot Hospital. Both hospitals are state-owned hospitals located in Yaoundé, the capital of Cameroon, in the Centre Region; The Centre Region was ranked third (5.8%) over 10 in the CAMPFIA 2017 HIV prevalence ranking in Cameroon [24]. In Yaoundé, this prevalence was evaluated to 4.4%.

Inclusion and non-inclusion criteria

Our study included adults (aged over 21) living with HIV on first-line antiretroviral therapy followed up since at least 2 years in the two participating centers, who voluntarily accepted to take part in this study and signed the written consent form. However, we were excluded from this study: Alcoholic patients, pregnant women, patients with a blood pressure > 140/90 mmHg, diabetic patients, patients with nephropathy due to other than HIV/AIDS and/or its treatment, patients undergoing other treatment that may cause kidney failure and patients who had history of kidney transplant or dialysis.

Data collection

The study participants comprised of a subset of
187 well-documented HIV positive patients who were on ART for at least 2 years and registered for primary care at the Essos Hospital center or the Jamot Hospital. A standard questionnaire was used to capture the following informations: Demographic characteristics, ART regimen, duration on ART, renal function results at the time ART was started, and concomitant use of other potentially nephrotoxic agents.

**Laboratory procedures**

Urea and creatinine assay kits, as well as sampling and analysis equipment, were mainly provided by the hospital centers, other materials having been purchased from Yaoundé specialized stores. Blood samples were collected on dry tubes using needles adapted for the vacutainer system. In order to obtain the serum, the samples were centrifuged at 3000 to 4000 rpm for 5 minutes after coagulation. The serum collected was immediately used for the determination of biochemical markers of renal damage, namely serum urea and creatinine, in a Biochrom Libra S12 spectrophotometer. Urea was analyzed using the kinetic method [25]. For serum creatinine, the Jaffe kinetic method was used [25]. Since serum creatinine alone does not provide sufficient information on renal function, because of the physiological differences of patients related to age, sex or race, the estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) equation, which considers all those factors [26-28]:

\[
\text{GFR in mL/min/1.73 m}^2 = 175 \times \text{Serum Cr}^{1.154} \times \text{age}^{0.203} \times 1.212 \times (\text{if patient is black}) \times 0.742 \times (\text{if female}).
\]

**Statistical analysis**

Data were entered into Microsoft excel 2016, and then analysed with the XLSTAT 2020.4 software. The evolution of the quantitative parameters before and after ART initiation was analysed by the Wilcoxon signed-rank test or by the paired t-test when applicable. Categorical data were compared using chi-square test. A P-value < 0.05 was considered statistically significant.

**Ethical consideration**

Data were collected after administrative authorizations were obtained from the Essos Hospital Center and the Jamot Hospital. Ethical clearance was obtained from the Centre Regional Ethics Committee for Human Health Research. This project was carried out with informed consent without financial contribution from patients in strict respect of medical confidentiality. Patients were free to accept our study or not after understanding its scope and scientific interest. Each file has been identified by an anonymous number.

**Results**

**Demographic characteristics and regimen**

Our sample consisted of 187 patients, grouped according to the medications received. A majority of the participants on ART were on tenofovir (TNF) and lamivudine (3TC)-based regimen (Figure 1).

Among the 187 participants, there were 134 women (71.66%) and 53 men (28.34%), therefore a female predominance. The participants had ages ranging from 24 to 77 years, with a mean age of 42.47 ± 10.68. Women’s mean age was 42.3 ± 11.0 years while men had a mean age of 42.5 ± 10.1 years.

![Figure 1: Repartition of the subjects according to ART regimen.](image-url)
Table 1: Distribution of the study population by gender for each ART regimen.

| ART Regimen            | Women n (%) | Mean Age (± Standard Deviation) | Men n (%) | Mean Age (± Standard Deviation) | Total n (%) |
|------------------------|-------------|--------------------------------|-----------|--------------------------------|-------------|
| AZT + 3TC + NVP        | 16 (76.2)   | 42.2 ± 12.2                   | 5 (23.8)  | 39.0 ± 9.3                   | 21 (100)    |
| AZT + TNF + NVP        | 5 (71.5)    | 47.2 ± 10.8                   | 2 (28.5)  | 35.5 ± 12.0                   | 7 (100)     |
| 3TC + TNF + EMB        | 14 (87.5)   | 40.0 ± 9.9                    | 2 (12.5)  | 49.0 ± 11.2                   | 16 (100)    |
| D4T30 + 3TC + EFV      | 8 (80)      | 45.0 ± 12.6                   | 2 (20)    | 39.5 ± 6.3                    | 10 (100)    |
| D4T40 + 3TC + NVP      | 9 (75)      | 45.1 ± 12.0                   | 3 (25)    | 36.6 ± 7.5                    | 12 (100)    |
| ABC + 3TC + EFV        | 2 (66.7)    | 41.0 ± 15.5                   | 1 (33.3)  | 60.0                          | 3 (100)     |
| TNF + 3TC + EFV        | 47 (63.5)   | 41.4 ± 11.2                   | 27 (36.5) | 43.0 ± 10.3                   | 74 (100)    |
| TNF + 3TC + EFV + CTM  | 20 (71.4)   | 41.6 ± 11.8                   | 8 (28.6)  | 48.0 ± 5.3                    | 28 (100)    |
| TNF + 3TC + EFV + INH  | 6 (100)     | 45.4 ± 8.6                    | 0 (0.0)   | NA                           | 6 (100)     |
| TNF + 3TC + EFV + CTM + INH | 3 (50) | 41.7 ± 3.1                    | 3 (50.0)  | 39.3 ± 8.9                    | 6 (100)     |
| TNF + 3TC              | 4 (100)     | 44.0 ± 6.6                    | 0 (0.0)   | NA                           | 4 (100)     |
| All regimen            | 134 (71.66) | 42.3 ± 11.0                   | 53 (28.34)| 42.9 ± 10.0                   | 187 (100)   |

NA: Not Applicable.

Table 2: Serum urea and creatinine levels before and after initiation to treatment according to ART regimen.

| ART Regimen            | Before Mean Serum Urea Level (mmol/l) | After Mean Serum Urea Level (mmol/l) | Significant p-value (< 0.05) | Before Mean Serum Creatinine Level (µmol/l) | After Mean Serum Creatinine Level (µmol/l) | Significant p-value (< 0.05) |
|------------------------|--------------------------------------|--------------------------------------|------------------------------|---------------------------------------------|-------------------------------------------|------------------------------|
|                        | Women Reference Values (2.5-7)       | Men Reference Values (3.0-7.5)       |                               | Women Reference Values (53-115)             | Men Reference Values (88-150)             |                              |
|                        | Before | After | | Before | After | | Before | After | | Before | After | | Before | After |                               |
| AZT + 3TC + NVP        | 4.25 ± 1.25 | 5.23 ± 2.16 | Yes | 4.39 ± 1.28 | 5.29 ± 2.61 |                               | 85.1 ± 18.3 | 64.2 ± 11.3 | Yes | 91.9 ± 30.3 | 61.8 ± 18.7 |                               |
| AZT + TNF + NVP        | 4.76 ± 0.36 | 4.52 ± 2.0 |                               | 4.49 ± 1.64 | 6.24 ± 2.94 |                               | 56.2 ± 30.8 | 81.3 ± 14.5 | Yes | 44.2 ± 25.0 | 83.9 ± 18.7 |                               |
| 3TC + TNF + EMB        | 4.06 ± 1.59 | 4.95 ± 2.0 |                               | 3.82 ± 1.64 | 3.91 ± 3.17 |                               | 70.2 ± 15.9 | 58.7 ± 15.7 | Yes | 79.5 ± 25.0 | 66.3 ± 31.2 |                               |
| D4T30 + 3TC + EFV      | 3.62 ± 1.60 | 4.59 ± 2.31 |                               | 5.41 ± 0.58 | 3.99 ± 2.35 |                               | 81.9 ± 25.8 | 32.0 ± 36.4 | | 110.5 ± 18.7 | 75.1 ± 6.2 |                               |
| D4T40 + 3TC + NVP      | 3.70 ± 2.15 | 6.43 ± 1.27 | Yes | 5.43 ± 0.41 | 2.77 ± 0.69 | Yes |                              |                               |                               |                              |                               |                              |
| ABC + 3TC + EFV        | 4.32 ± 0.23 | 4.07 ± 0.58 |                               | 3.99 ± 0.0 | 4.82 ± 0.0 | NA                           | 91.9 ± 30.3 | 61.8 ± 18.7 |                               |                               |                               |                               |
| TNF + 3TC + EFV        | 3.94 ± 0.82 | 3.23 ± 0.66 |                               | 3.99 ± 0.47 | 3.33 ± 0.47 |                               | 56.2 ± 30.8 | 81.3 ± 14.5 | Yes | 44.2 ± 25.0 | 83.9 ± 18.7 |                               |
| TNF + 3TC + EFV + CTM  | 4.60 ± 0.41 | 4.71 ± 0.91 |                               | 3.99 ± 0.69 | 5.2 ± 0.45 | Yes | 70.2 ± 15.9 | 58.7 ± 15.7 | Yes | 79.5 ± 25.0 | 66.3 ± 31.2 |                               |
| TNF + 3TC + EFV + CTM + INH | 3.08 ± 0.58 | 5.07 ± 0.35 | yes | NA | NA | NA |                              | 81.9 ± 25.8 | 32.0 ± 36.4 |                               | 110.5 ± 18.7 | 75.1 ± 6.2 |                               |
| TNF + 3TC              | 0.95 ± 1.12 | 1.54 ± 1.79 |                               | NA | NA | NA |                              |                               |                               |                              |                               |                               |                               |
age of 42.9 ± 10.0 years (Table 1).

**Determination of serum urea and creatinine**

By comparing the mean urea level of patients reported before ART initiation to the values obtained after ART initiation (Table 2), we found a significant increase for D4T40 + 3TC + NVP and TNF + 3TC + EFV + INH regimen in women and for TNF + 3TC + EFV + CTM in men (p-value 0.011, 0.03 and 0.03 respectively). However, we found a significant decrease for D4T40 + 3TC + NVP in men (p-value 0.03). The mean serum creatinine increased significantly for women following regimen AZT + TNF + NVP and D4T40 + 3TC + NVP (p-value 0.022 and 0.028 respectively). In men, a significant increase in serum creatinine was only observed for those on AZT + TNF + NVP (p-value 0.03). There was rather a decrease in blood creatinine for AZT + 3TC + NVP regimen in women (p-value 0.0032).

**Assessment of renal function**

The eGFR was calculated, for all patients, using the MDRD method. Since this method considers gender, the calculated averages relate to patients of both sexes combined, for each group. Figure 2 shows that, on average, eGFR decreased significantly after treatment for the AZT + TNF + NVP (p = 0.015), D4T40 + 3TC + NVP (p = 0.016) and TNF + 3TC + EFV + INH (p = 0.03) regimen. We noted rather a significant increase for AZT + 3TC + NVP (p = 0.0001), 3TC + TNF + EMB (p = 0.032) and D4T30 + 3TC + EFV (p = 0.032) regimen.

Table 3 displays the prevalence of renal dysfunction within the groups. Of the total study population, 5 (3%) had eGFR < 60 ml/min/1.73 m² before ART initiation, and 15 (8%) after ART initiation. The difference in prevalence of renal dysfunction between study groups changed from no significant before ART initiation to significant after ART initiation (chi-square p-value 0.117 and 0.0002 respectively before and after ART initiation). Patients treated with D4T40 + 3TC + NVP had a higher prevalence of renal dysfunction (41.67%) after ART initiation, followed by those treated with TNF + 3TC +

| ART Regimen          | Before   | After   | p-value |
|----------------------|----------|---------|---------|
| D4T40 + 3TC + NVP   | 72.3 ± 46.6 | 109.0 ± 70 | Yes     |
| ABC + 3TC + EFV     | 75.5 ± 33.09 | 72.8 ± 11.8 | 174.8 ± 0.0 | 96.2 ± 0.0 | NA |
| TNF + 3TC + EFV     | 78.9 ± 17.6 | 84.9 ± 21.5 | 93.0 ± 15.8 | 94.1 ± 17.9 |
| TNF + 3TC + EFV + CTM| 80.4 ± 15.1 | 81.5 ± 15.3 | 82.2 ± 18.5 | 87.3 ± 17.3 |
| TNF + 3TC + EFV + INH| 70.8 ± 18.0 | 91.4 ± 8.95 | NA | NA | NA |
| TNF + 3TC + EFV + CTM + INH| 85.6 ± 12.7 | 82.7 ± 20.2 | 89.5 ± 31.3 | 74.4 ± 27.2 |
| TNF + 3TC            | 77.9 ± 26.4 | 78.8 ± 24.7 | NA | NA | NA |

NA: Not Applicable.

Figure 2: The estimated glomerular filtration rate (eGFR) according to the ART regimen. Error bars represent the standard deviation to the mean.
panied by a significant decrease in mean eGFR for the same regimen, as well as for TNF + 3TC + EFV + INH. In the case of AZT + TNF + NVP and TNF + 3TC + EFV + INH combinations, we believe that tenofovir (TNF) could be responsible for this renal dysfunction. Indeed, several observations of tenofovir-induced nephropathies have been published [30-32]. This nucleotide inhibitor of HIV reverse transcriptase can cause renal failure associated with tubular abnormalities that may be due to down-regulation of diverse ion transporters. This nephrotoxicity of tenofovir has been confirmed by reports of reversal of renal toxicity on tenofovir withdrawal [33-35]. In addition, we noticed in our study that, for 3 of the 5 tenofovir-based combinations for which there was no decrease in mean eGFR, the prevalence of patients with eGFR < 60 ml/min/1.73 m² after initiation of ART has nevertheless increased, as well as for the combinations for which the mean eGFR decreased. Some studies carried out in Cameroon have also revealed renal toxicity of tenofovir-based combinations [16,18]. By contrast, another research conducted in Cameroon revealed the lack of nephrotoxicity of various antiretroviral treatments [17]. But, regarding this other study, the nature of the ART combinations had not been specified.

The possibility of nephrotoxic interaction between isoniazid (an anti-tuberculosis drug) and other drugs also exists [36,37]. Chia-Hao, et al. [38] also reported a 7.1% prevalence of acute kidney injury in patients on anti-tuberculosis treatment. The decrease in mean eGFR observed in patients on TNF + 3TC + EFV + INH could therefore be partly due to the effect of isoniazid (INH). This supposedly harmful effect of INH could be rectified by the concomitant use of another antibiotic drug, cotrimoxazole, according to the results of the present study.

Furthermore, the decrease in eGFR observed in pa-

### Table 3: Prevalence of renal dysfunction within the groups.

| Before ART Initiation | After ART Initiation |
|-----------------------|---------------------|
|                       | eGFR ≥ 60 | eGFR < 60 | eGFR ≥ 60 | eGFR < 60 | Total |
| AZT/ + 3TC + NVP      | 20 (95.24%) | 1 (4.76%) | 21 (100%) | 0 (0%)    | 21 (100%) |
| AZT + TNF + NVP       | 7 (100%)   | 0 (0%)    | 7 (100%)  | 0 (0%)    | 7 (100%)  |
| 3TC + TNF + EMB       | 16 (100%)  | 0 (0%)    | 16 (100%) | 0 (0%)    | 16 (100%) |
| D4T30 + 3TC + EFV     | 9 (90%)    | 1 (10%)   | 10 (100%) | 0 (0%)    | 10 (100%) |
| D4T40 + 3TC + NVP     | 12 (100%)  | 0 (0%)    | 7 (58.33%)| 5 (41.67%)| 12 (100%) |
| ABC + 3TC + EFV       | 2 (66.67%) | 1 (33.33%)| 3 (100%)  | 0 (0%)    | 3 (100%)  |
| TNF + 3TC + EFV       | 72 (97.3%) | 2 (2.7%)  | 68 (91.89%)| 6 (8.1%)  | 74 (100%) |
| TNF + 3TC + EFV + CTM | 28 (100%)  | 0 (0%)    | 27 (96.43%)| 1 (3.57%) | 28 (100%) |
| TNF + 3TC + EFV + INH | 6 (100%)   | 0 (0%)    | 4 (66.67%)| 2 (33.33%)| 6 (100%)  |
| TNF + 3TC + EFV + CTM + INH | 6 (100%) | 0 (0%) | 6 (100%) | 0 (0%) | 6 (100%) |
| TNF + 3TC             | 4 (100%)   | 0 (0%)    | 3 (75%)   | 1 (25%)   | 4 (100%)  |
| All regimen           | 182 (97.33%)| 5 (2.67%) | 172 (91.98%)| 15 (8.02%)| 187 (100%) |

eGFR is done in ml/min/1.73 m².
tients treated with D4T40 + 3TC + NVP (stavudine 40 mg, lamivudine and nevirapine) is not a surprise, as some studies show nephrotoxicity of these three drugs. Stavudine and lamivudine have previously been associated with tubular dysfunction [39,40]. Both of these molecules, like tenofovir, are nucleoside reverse transcriptase inhibitors. It is recognized, according to some reports, that nephrotoxicity of these antiviral analogue nucleotides is explained by cellular accumulation through the entry of the organic anion transporters and decreased efflux into tubular lumen. Note also that two drug combinations for which a decrease in eGFR has been observed in the present study include nevirapine. Although this non-nucleoside reverse transcriptase inhibitor has not been implicated in nephropathies, further studies need to be conducted to determine whether its association with other molecules could exacerbate nephrotoxicity.

In our study, there was a decrease in blood creatinine for AZT + 3TC + NVP regimen in women. This decrease in creatinine concentration was accompanied by a significant increase in mean eGFR for the same regimen, as well as for 3TC + TNF + EMB and D4T30 + 3TC + EFV regimen. This improvement in eGFR could be due to reduction of HIV development by these drug combinations. Some renal complications often observed in patients may indeed be related to the virus itself, according to studies carried out in Cameroon and elsewhere in the world [41-43]. It has been reported that control of viral replication by ART has a considerable improvement in renal function in patients initially having a drop in glomerular filtration rate (< 89 ml/min/1.73 m²) and a low level of CD4 (< 200/mm³) [44]. The renal damage related to HIV itself and not to its treatment could therefore be more common than we think, and controlling virus activity with ART may therefore result in improved kidney function. Moreover, it may be that combination of tenofovir with lamivudine and emtricitabine (3TC + TNF + EMB) reverses its nephrotoxicity. Indeed, the side effects of a drug are sometimes lifted by the activity of other drugs taken in combination, as has already been demonstrated for the case of taking tenufovir concomitantly with rosiglitazone. Rosiglitazone is a drug widely used to treat patients with type 2 diabetes mellitus. It induces the expression of many of the same transporters that tenufovir down-regulates, thus reversing tenufovir-induced tubular nephrotoxicity and thereby improving glomerular filtration rate [45]. As regards D4T30 (stavudine 30 mg), it could be that stavudine, at a reduced dose in this case, unlike D4T40 (stavudine 40 mg), is less toxic, as some other studies have shown [46,47].

The present study has some limitations. Firstly, the relatively small sample size meant that for some patient groups there were less than 10 participants, or even less than 5. It is thus possible that the absence of significance in some differences observed was just a reflection of the limited statistical power. However, the study was conducted in two distinct centres, which shares the typical characteristics of many hospitals in Cameroon. This dispersion of study centers can act in favor of the representativeness of the sample. The second limitation of this study is that patient treatment for HIV had been on treatment for different lengths of time, thus, this study minimizes the effect of the duration of treatment. However, as already mentioned, all patients had been on the same ART regimen for at least 2 years, which is a long enough time for the biochemical signs of chronic kidney disease to be considered. Moreover, Achu, et al. [17] demonstrated in another study carried out in Cameroon the lack of association between decreased renal function to duration on HAART regimen. Another limit of this study is that, retrospective data of renal function biomarkers were sufficient to obtain the eGFR at several time intervals only for 6 of the ART regimen, so the data presented here just correspond to 2 measurements, in order to harmonize the conclusions specific to the various regimen. Finally, data on other biochemical parameters such as albuminuria and hematuria were incomplete and could not be presented here. However, it is accepted that an eGFR < 60 ml/min/1.73 m² is sufficient to diagnose renal dysfunction, and it is this limit that we set to determine the proportions of patients with renal insufficiency [48].

Conclusion

The study we conducted is a continuation of the work done by many researchers on the evaluation of ARVs renal toxicity. We have not only acquired specific information for the different drug combinations above mentioned, but have broadened the scope of the few studies already done in Cameroon. Further studies must be carried out in order to confirm or even better understand the cellular and molecular aspects of the interactions of stavudine 40 or tenofovir-based combinations. This can help establish effective preventive and therapeutic pharmacological interventions. It is imperative in that not only the mean eGFR of patients on some of those ART regimens significantly decreased during treatment, but also a considerable percentage of these patients had their eGFR decline below the threshold of 60 ml/min/1.73 m². Waiting for other studies involving a larger sample of patients recruited from a large number of health centers, treatment with AZT + 3TC + NVP, 3TC + TNF + EMB or D4T30 + 3TC + EFV regimen may be recommended in Cameroon, since no confirmed renal toxicity has been observed in this study in patients on these regimen. These combinations would be rather protective for renal function. This recommendation must at least be taken into account for the case of black patients, while waiting for our observations to be verified also for other races.

Conflicts of Interest

The authors declare that they have no conflict of interest.
Aknowledgements

We are grateful to the administrative and technical staff of the Essos Hospital Center, the Jamot Hospital and to the administrative staff of the Faculty of Health Sciences of the Protestant University Institute of Yaounde, Cameroon, for their support in the completion of this study.

References

1. UNAIDS (2020) Factsheet 2020 - Latest statistics on the status of the AIDS epidemic.
2. Moroni M, Antinori S (2003) HIV and direct damage of organs: Disease spectrum before and during the highly active antiretroviral therapy era. AIDS 17: S51-S64.
3. Izzedine H, Launay-Vacher V, Deray G (2005) Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 45: 804-817.
4. Han TM, Naicker S, Ramdial PK, Assounga AG (2006) A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int 69: 2243-2250.
5. Rao TK, Filippone EJ, Nicastri AD, Landesman SH, Frank E, et al. (1984) Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 310: 669-673.
6. Andiman AW, Chernoff MC, Mitchell C, Purswani M, Olemske J, et al. (2009) Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: Associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. Pediatr Infect Dis J 28: 619-625.
7. Lene R, Mocroft A, Lundgren JD (2014) Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons. Curr Opin HIV AIDS 9: 41-47.
8. Antoniou T, Raboud JM, Chirhin S, Yoong D, Govan V, et al. (2005) Incidence of and risk factors for tenofovir-induced nephrotoxicity: A retrospective cohort study. HIV Med 6: 284-290.
9. Ryom L, Mocroft A, Lundgren J (2012) HIV therapies and the kidney: Some good, some not so good? Curr HIV/AIDS Rep 9: 111-120.
10. Brennan A, Evans D, Maskew M, Naicker S, Ives P, et al. (2011) Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS 25: 1603-1609.
11. Eluwa GI, Badru T, Agu KA, Akpogbe KJ, Chabikuli O, et al. (2012) Adverse drug reactions to antiretroviral therapy (ARVs): Incidence, type and risk factors in Nigeria. BMC Clin Pharmacol 12: 7.
12. Burroughs VJ, Maxey RW, Levy RA (2002) Racial and ethnic differences in response to medicines: Towards individualized pharmaceutical treatment. J Natl Med Assoc 94: 1-26.
13. Ortega VE, Meyers DA (2014) Pharmacogenetics: Implications of race and ethnicity on defining genetic profiles for personalized medicine. J Allergy Clin Immunol 133: 16-26.
14. UNAIDS (2019) Cameroon data sheet 2019.
15. Nsagha DS, Pokam BT, Assob JCN, Nzunda AL, Kibu OD, et al. (2015) HAART, DOTs and renal disease of patients co-infected with HIV/AIDS and TB in the South West Region of Cameroon. BMC Public Health 15: 1040.
16. Fokunang CN, Banin AN, Kouanfack C, Ngogang JY (2010) Evaluation of hepatotoxicity and nephrotoxicity in HIV patients on highly active anti-retroviral therapy. J AIDS HIV Res 2: 48-57.
17. Ntorbugwe ACA, Asongalem AE, Nchotu BR, Tanue EA, Wirsiy FS, et al. (2020) Assessment of the effect of HAART on renal function of HIV patients attending the Bamenda Regional Hospital, Cameroon. TOAJD 14: 1-9.
18. Kamga WR, Taheu C, Tchatchouang S, Fokam J (2020) Evaluation of nephrotoxicity among first-line antiretroviral therapy-experienced patients at the Yaounde Central Hospital. Biomed J Sci & Tech Res 25: 19411-19415.
19. Luma HN, Doualla MS, Choukem SP, Temfack E, Ashuntantang G, et al. (2012) Adverse drug reactions of Highly Active Antiretroviral Therapy (HAART) in HIV infected patients at the General Hospital, Douala, Cameroon: A cross sectional study. Pan Afr Med J 12: 87.
20. Dimala CA, Bechem NN, Aroke D, Kadia BM (2017) Motives for change of first-line antiretroviral therapy regimens in an unselected cohort of HIV/AIDS patients at a major referral centre in South-west Cameroon. BMC Res Notes 10: 623.
21. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, et al. (2010) Systematic review and meta-analysis: Renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 51: 496-505.
22. Mtsi TJ, Ndhlouvo CE, Maponga CC, Morse GD (2019) Tenofovir-associated kidney disease in Africans: A systematic review. AIDS Res Ther 16: 12.
23. National Kidney Foundation K-DOQI (2007) Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Clin Rev Bone Miner Metab 5: 53-67.
24. ICAP (2018) Cameroon population based HIV impact assessment - CAMPHIA 2017.
25. Thomas L (1998) Clinical laboratory diagnostics: Use and assessment of clinical laboratory results. TH-Books Verlagsgesellsschaft, Frankfurt/Main.
26. Levey AS, MDRD GFR equation.
27. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470.
28. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, et al. (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247-254.
29. Valdigué P (2000) Biochimie Clinique. (2nd edn), Editions Médicales Internationals.
30. Perazella MA (2010) Tenofovir-induced kidney disease: An acquired renal tubular mitochondrialopathy. Kidney Int 78: 1060-1063.
31. Novick TK, Choi MJ, Rosenberg AZ, McMahon BA, Fine D, et al. (2017) Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report. Medicine (Baltimore) 96: e8046.
32. Kalyesubula R, Perazella MA (2011) Nephrotoxicity of HAART. AIDS Res Treat 2011: 562790.
33. Some F, Koech M, Chesire E, Kigen G (2017) Reversal of tenofovir induced nephrotoxicity: Case reports of two patients. Pan Afr Med J 27: 126.
42. Wyatt CM, Klotman PE, D’Agati VD (2008) HIV-associated nephropathy: Clinical presentation, pathology, and epidemiology in the era of antiretroviral therapy. Semin Nephrol 28: 513-522.

43. Kalayjian RC (2010) The treatment of HIV-associated nephropathy. Adv Chronic Kidney Dis 17: 59-71.

44. Kalayjian RC, Franceschini N, Gupta SK, Szczech LA, Mupere E, et al. (2008) Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS 22: 481-487.

45. Liborio AB, Andrade L, Pereira LVB, Sanches TRC, Shimizu MH, et al. (2008) Rosiglitazone reverses tenofovir-induced nephrotoxicity. Kidney Int 74: 910-918.

46. Maskew M, Westreich D, Fox MP, Maotoe T, Sanne IM (2012) Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: A cohort study among HIV-infected adults initiating HAART in South Africa. J Int AIDS Soc 15: 13.

47. Pujades-Rodriguez M, Dantony E, Pinoges L, Ecochard R, Etard JF, et al. (2011) Toxicity associated with stavudine dose reduction from 40 to 30 mg in first-line antiretroviral therapy. PLoS One 6: e28112.

48. Courtney AE, Maxwell AP, Fogarty DG (2007) Using estimated glomerular filtration rate (eGFR) to help manage patients with chronic kidney disease. Ulster Med J 76: 154-156.